Kevin Koch is President and Chief Executive Officer of Edgewise Therapeutics, Inc. (EWTX). The company reported total compensation of $7,359,546 for fiscal year 2025.
| Salary | $670,000 |
|---|---|
| Bonus | — |
| Stock awards | $1,171,625 |
| Option awards | $5,041,621 |
| Non-equity incentive plan | $462,300 |
| Pension and non-qualified deferred compensation | — |
| All other compensation | $14,000 |
| Total | $7,359,546 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Edgewise Therapeutics, Inc. filed April 23, 2026, accession 0001104659-26-047688.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | President and Chief Executive Officer | $670,000 | — | $1,171,625 | $5,041,621 | $462,300 | — | $14,000 | $7,359,546 |
| FY2024 | President and Chief Executive Officer | $618,675 | — | $1,225,469 | $5,300,903 | $442,353 | — | $13,800 | $7,601,200 |
| FY2023 | President and Chief Executive Officer | $594,880 | — | $0 | $3,070,335 | $297,440 | — | $13,200 | $3,975,855 |
Totals as disclosed in each year's own compensation disclosure for Edgewise Therapeutics, Inc..
| Peer-group chief executive median | $7,182,067 |
|---|---|
| Difference from that median | $177,479 |
| Percentile within the disclosed peer group | 50th |
| Peers with a disclosed figure | 14 |
Medians and percentiles are computed across the peer group Edgewise Therapeutics, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Kevin Koch this page | President and Chief Executive Officer | $7,359,546 |
| Robert Blaustein | Former Chief Development Officer | $4,567,385 |
| Michael Nofi | Chief Financial Officer | $4,284,659 |
| Behrad Derakhshan | Chief Operating Officer | $2,933,228 |
| Joanne Donovan | Chief Medical Officer | $2,785,306 |
| Alan Russell | Co-Founder and Chief Scientific Officer | $2,734,849 |
| R. Michael Carruthers | Former Chief Financial Officer | $2,587,465 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Edgewise Therapeutics, Inc. compensation brief.
Kevin Koch's compensation sits inside Edgewise Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.